Gain Therapeutics, Inc. (GANX)
Discovers small molecules that bind hidden protein sites to treat neurological and genetic diseases.
$1.73-0.07%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+20.1%
The outlook
GANX trades well below its 50- and 200-day moving averages and sits near its 52-week low. Analyst coverage leans bullish on fundamentals, with an average price target suggesting significant upside, though the overall StockGlow score reflects bearish sentiment. The stock's recent weakness contrasts sharply with analyst expectations.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range11% of the way from its 52-week low to high
Price targetAvg target +316% vs current price
Analyst price target
~12-month · 5 analysts$7.20average target+316.2% vs now
Now $1.73
Low $5.00High $8.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$73.8M
52-wk high
$4.34
52-wk low
$1.41
50-day avg
$1.78
200-day avg
$2.20
Trailing P/E
—